- Home
- JZXN vs SNGX Comparison
JZXN vs SNGX Comparison
Compare JZXN & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JZXN | SNGX |
|---|---|---|
| Founded | 2019 | 1987 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Retail-Auto Dealers and Gas Stations | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.2M | 14.4M |
| IPO Year | 2021 | 1987 |
Fundamental Metrics
Financial Performance| Metric | JZXN | SNGX |
|---|---|---|
| Price | $2.62 | $1.12 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | ★ 1.4M | 188.2K |
| Earning Date | 03-05-2026 | 03-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $97,465.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.03 | $1.02 |
| 52 Week High | $312.80 | $6.23 |
Technical Indicators
Market Signals| Indicator | JZXN | SNGX |
|---|---|---|
| Relative Strength Index (RSI) | 65.59 | 35.73 |
| Support Level | $1.03 | $1.02 |
| Resistance Level | $2.01 | $1.18 |
| Average True Range (ATR) | 0.33 | 0.08 |
| MACD | 0.04 | -0.02 |
| Stochastic Oscillator | 80.90 | 23.86 |
Price Performance
Historical ComparisonAbout JZXN Jiuzi Holdings Inc.
Jiuzi Holdings Inc operates as a franchise under the brand name Jiuzi. It sells new energy vehicles in third-fourth tier cities in China. The firm also sells plug-in electric vehicles on demand from vehicle buyers. Its operating segments are propretaey product; and resale of sourced Equipment and accessories from third party products. The company generates a majority of its revenue from the propretaey product segment. Geographically, the firm operates in China.
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).